CD274 and non-small cell lung carcinoma: NCCN guidelines also recommends atezolizumab as an adjuvant therapy for patients who have previously received adjuvant chemotherapy with completely resected stage IIB to IIIA or high-risk stage IIA NSCLC and PD-L1 ≥1%, according to clinical trial results from another phase 3 randomized trial-IMpower010 which compared adjuvant therapy with atezolizumab versus best supportive care in patients with resected early-stage NSCLC (12).